ARQ-154 is under clinical development by Arcutis Biotherapeutics and currently in Pre-Registration for Seborrhea. According to GlobalData, Pre-Registration drugs for Seborrhea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how ARQ-154’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ARQ-154 overview

ARQ-154 is under development for the treatment of seborrheic dermatitis, scalp psoriasis and plaque psoriasis.The drug candidate is formulated as a foam and administered by topical route. It acts by targeting phosphodiesterase 4 (PDE4).

Arcutis Biotherapeutics overview

Arcutis Biotherapeutics (Arcutis), a subsidiary of Allspring Global Investments Holdings LLC, is a biopharmaceutical company. The company is in developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. Its pipeline products includes a topical roflumilast cream, ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. The company also investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.

For a complete picture of ARQ-154’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.